|BUY||$73.620||BULLISH on GLOBAL STOCKS||GLOBAL||Yes|
It is a really strong global pharma company. They are turning around their eye care business acquisition and their cardiac drug which had a bungled launch. If they are successful they will do quite well. It could be a blockbuster.
Managing Dir. & Portfolio Manager, Gluskin Sheff & Associates